A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease.
Historically, standard treatment of hepatitis C virus (HCV) infection in patients with renal impairment has been limited by low cure rates and poor tolerability. The introduction of direct-acting antivirals (DAAs) has revolutionized the treatment of HCV with impressive cure rates >90% and low rates of adverse events. Despite these major advancements, treatment of patients with HCV and advanced chronic kidney disease (CKD) is a major challenge due to the lack of efficacy and safety data in this patient population. The purpose of this review is to summarize the available data for efficacy and safety of the following DAAs in treating HCV patients with advanced Stage 4 and 5 CKD: simeprevir, sofosbuvir, ledipasvir, ombitasvir, paritaprevir, dasabuvir, grazoprevir, elbasvir and daclatasvir.
Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
Anna
A
Maruyama
Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, BC, Canada.
Nilufar
N
Partovi
The Division of Gastroenterology, Vancouver General Hospital, Vancouver, BC, Canada.
Eric M
EM
Yoshida
The Division of Gastroenterology, Vancouver General Hospital, Vancouver, BC, Canada.
Siegfried R
SR
Erb
The Division of Gastroenterology, Vancouver General Hospital, Vancouver, BC, Canada.
Vladimir Marquez
VM
Azalgara
Pharmaceutical Sciences Clinical Service Unit, Vancouver General Hospital, Vancouver, BC, Canada.
Trana
T
Hussaini
D000998:Antiviral Agents / Q000627:therapeutic use*; D016174:Hepacivirus / Q000187:drug effects*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy* / Q000821:virology
D000998:Antiviral Agents
CKD; ESRD; chronic renal failure; direct-acting antivirals; hepatitis C